Orally-active antidiuretic (FE 106483)
A recent breakthrough by Ferring scientists led to the discovery of a family of orally active non-peptide vasopressin agonists that provide the basis for a new generation of antiduretic compounds.
The first drug that emerged from the discovery is FE 106483. The hallmarks that distinguish this new generation of compounds are high selectivity for its receptor, fast onset of action, high oral availability and short half-life. FE 106483 is currently undergoing clinical phase II trials.
Nocturia
Ferring’s antidiuretic compound, MINIRIN (desmopressin), has completed its clinical development programme for the treatment of nocturia and has recently been approved for this indication in a number of countries worldwide. Many other countries are also considering an approval for this indication.
Nocturia is defined as the night-time urge to void and is a voluntary act of micturition (urination). The cause of nocturia is multifactorial with about 70% of the nocturic population suffering from nocturnal polyuria where urinary production during the night exceeds the bladder's capacity.
Prostate cancer - degarelix
Ferring's research into the management of prostate cancer has focused on the gonadotropin-releasing hormone (GnRH) receptor. DECAPEPTYL (triptorelin) was developed as the first generation of GnRH analogues, and this approach is now regarded as an established method for treating prostate cancer.
In collaboration with recognised scientists from the world-renowned Salk Institute, in San Diego US, Ferring scientists have discovered a new generation of GnRH receptor analogues. The first in this family of drugs is degarelix, a potent and selective GnRH receptor blocker.
The research programme started in 1996 in the GnRH area and is currently in phase III clinical trials. A worldwide clinical development programme is ongoing and focuses on developing a one-month a three-month sustained released parenteral depot formulation.
This type of drug may also treat a number of other diseases and Ferring is actively investigating other potential indications.